Establishing pre-analytical requirements and maximizing peptide recovery in the analytical phase for mass spectrometric quantification of amyloid-ß peptides 1-42 and 1-40 in CSF.

Forgrave, Lauren M; van der Gugten, J Grace; Nguyen, Quyen; DeMarco, Mari L

Forgrave, Lauren M; van der Gugten, J Grace; Nguyen, Quyen; DeMarco, Mari L.

Afiliação

Forgrave LM; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
van der Gugten JG; Department of Pathology and Laboratory Medicine, St. Paul's Hospital, Providence Health Care, Vancouver, Canada.
Nguyen Q; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.
DeMarco ML; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.

Clin Chem Lab Med ; 60(2): 198-206, 2022 01 27.

Article em En | MEDLINE | ID: mdl-34881836

Assuntos

Doença de Alzheimer; Fragmentos de Peptídeos; Doença de Alzheimer/diagnóstico; Peptídeos beta-Amiloides/líquido cefalorraquidiano; Biomarcadores/líquido cefalorraquidiano; Humanos; Espectrometria de Massas; Fragmentos de Peptídeos/líquido cefalorraquidiano; Reprodutibilidade dos Testes

Palavras-chave

Alzheimer's disease; amyloid-ß peptides; biomarkers; mass spectrometry; pre-analytical phase; therapeutics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fragmentos de Peptídeos / Doença de Alzheimer Tipo de estudo: Diagnostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google